Source Natural

Who are the top shareholders of the Source Natural?

The top shareholder of Source Natural is Sriveda Sattva Private Limited, owning 74.37% of the shares, followed by public shareholder Guttikonda Vara Lakshmi with 2.96%. Individual investors hold 19.98%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Source Natural include Sriveda Sattva Private Limited, which holds a significant 74.37% of the shares, making it the largest promoter. The highest public shareholder is Guttikonda Vara Lakshmi, who owns 2.96% of the shares. Additionally, individual investors collectively hold 19.98% of the company's shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

Who are in the management team of Source Natural?

As of March 2023, the management team of Source Natural includes Narayana Narasimhan (Chairman), Arvind Varchaswi N (Managing Director), Tejagna Kashmira Katpitia (Executive Director), and several independent directors: Gowra Srinivas, Chandrakant Laxminarayan Rathi, Sriram Chandrasekaran, and Bharathy. Each member contributes to the company's governance and management.

As of March 2023, the management team of Source Natural includes the following individuals:<BR><BR>1. **Narayana Narasimhan** - Chairman & Non Executive Director<BR>2. **Arvind Varchaswi N** - Managing Director<BR>3. **Tejagna Kashmira Katpitia** - Executive Director & Wholetime Director<BR>4. **Gowra Srinivas** - Independent Director<BR>5. **Chandrakant Laxminarayan Rathi** - Independent Director<BR>6. **Sriram Chandrasekaran** - Independent Director<BR>7. **Bharathy** - Independent Director<BR><BR>Each member plays a significant role in the governance and management of the company.

Has Source Natural declared dividend?

No Dividend History Available

Who are the peers of the Source Natural?

Source Natural's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs, Ind-Swift, and Ajooni Biotech. Source Natural has a 1-year return of 105.50%, outperforming its peers, with Divi's Lab showing the highest return at 51.96% and Bharat Immunolog the lowest at -9.01%.

Peers: The peers of Source Natural are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs., Ind-Swift, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Average management risk is found at Mercury Labs. Below Average management risk is noted for Bharat Immunolog, Makers Labs., and Ajooni Biotech, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Source Natural, Divi's Lab., Torrent Pharma, Bharat Immunolog, Mercury Labs, Makers Labs., and Ajooni Biotech, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted for Source Natural and Torrent Pharma, and Below Average capital structure is observed in Bharat Immunolog, Mercury Labs, Makers Labs., and Ind-Swift.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Bharat Immunolog at -9.01%. Source Natural's 1-year return is 105.50%, which is significantly higher than both. Additionally, the peers with negative six-month returns include Mercury Labs, Bharat Immunolog, and Ind-Swift.

What is the technical trend for Source Natural?

As of June 2, 2025, Source Natural's technical trend is neutral with mixed signals, showing mildly bullish indicators on weekly MACD and Bollinger Bands, but mildly bearish on monthly MACD and daily moving averages.

As of 2 June 2025, the technical trend for Source Natural has changed from mildly bullish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST remains bullish on both weekly and monthly, and Dow Theory shows a mildly bullish trend weekly but mildly bearish monthly. Overall, the current technical stance is neutral with moderate strength, driven by conflicting signals from various indicators.

What does Source Natural do?

Source Natural Foods & Herbal Supplements Ltd specializes in allopathic and ayurvedic formulations within the pharmaceuticals and biotechnology sector. As of March 2025, it reported net sales of 161 Cr and a net profit of 6 Cr, with a market cap of INR 100 Cr.

Overview:<BR>Source Natural Foods & Herbal Supplements Ltd operates in the pharmaceuticals and biotechnology industry, focusing on providing allopathic and ayurvedic formulations.<BR><BR>History:<BR>The company was incorporated in 1995 as Inwinex Pharmaceuticals Limited and changed its name to Source Natural Foods & Herbal Supplements Limited in 2011-12. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 161 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 6 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 33.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 14.04%<BR>- Price to Book: 4.71<BR><BR>Contact Details:<BR>Address: 201 2nd Floor Sumeru Towers, 54/46 39 Jayanagar 4th Block Bangaluru Karnataka : 560041 <BR>Tel: 91-80-26087733 <BR>Email: info@source-natural.com <BR>Website: http://www.source-natural.com

How big is Source Natural?

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, with recent net sales of 44.94 Cr and a net profit of 2.91 Cr. Shareholder's funds are 19.45 Cr, and total assets amount to 23.65 Cr.

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 44.94 Cr and a Net Profit of 2.91 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 19.45 Cr and Total Assets of 23.65 Cr.

Is Source Natural overvalued or undervalued?

As of November 13, 2025, Source Natural is fairly valued with a PE ratio of 29.30 and a PEG ratio of 0.46, indicating reasonable valuation compared to peers, despite a 41.67% decline in stock performance over the past year.

As of 13 November 2025, the valuation grade for Source Natural has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 29.30, an EV to EBITDA of 16.59, and a PEG ratio of 0.46. These ratios suggest that while the company has growth potential, its current valuation aligns with its earnings and growth prospects.<BR><BR>In comparison to its peers, Source Natural's valuation appears reasonable. For instance, Sun Pharma has a significantly higher PE ratio of 36.15, while Cipla, considered attractive, has a PE of 22.65. The notable outperformance of Source Natural's PEG ratio at 0.46 compared to peers like Divi's Lab, which has a PEG of 1.99, further supports the conclusion that Source Natural is fairly valued. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 41.67% compared to the Sensex's gain of 8.74%, reinforcing the notion that the stock may not be undervalued at this time.

How has been the historical performance of Source Natural?

Source Natural has demonstrated significant growth in net sales and profitability, with net sales increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, and profit after tax rising from 2.12 Cr to 2.90 Cr during the same period. The company's total assets also grew from 21.45 Cr to 35.83 Cr, indicating a positive trend in financial performance.

Answer:<BR>The historical performance of Source Natural shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Source Natural's net sales have increased from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, demonstrating robust growth. The total operating income followed a similar trajectory, rising from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25. Operating profit, excluding other income, also saw an increase, reaching 5.15 Cr in Mar'25 from 3.56 Cr in Mar'23. Profit before tax improved from 2.74 Cr in Mar'23 to 3.58 Cr in Mar'25, while profit after tax rose from 2.12 Cr to 2.90 Cr in the same period. The company's earnings per share (EPS) increased from 3.29 in Mar'23 to 4.5 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 21.45 Cr in Mar'23 to 35.83 Cr in Mar'25, alongside total liabilities which increased from 21.45 Cr to 35.83 Cr. The cash flow from operating activities remained stable, with a net cash inflow of 0.00 Cr in Mar'25, while cash and cash equivalents at the end of the period were 7.00 Cr, consistent with the previous year. Overall, Source Natural has shown a positive trend in sales, profitability, and asset growth over the past few years.

When is the next results date for Source Natural Foods & Herbal Supplements Ltd?

The next results date for Source Natural Foods & Herbal Supplements Ltd is 28 May 2026.

The next results date for Source Natural Foods & Herbal Supplements Ltd is scheduled for 28 May 2026.

Are Source Natural Foods & Herbal Supplements Ltd latest results good or bad?

Source Natural Foods & Herbal Supplements Ltd's latest results show strong revenue growth with net sales up 30.86% year-on-year, but profitability is a concern due to low profit margins and high tax rates. While sales performance is positive, ongoing operational challenges suggest caution for investors.

Source Natural Foods & Herbal Supplements Ltd's latest results present a mixed picture. On one hand, the company reported impressive revenue growth, with net sales reaching ₹21.03 crores, marking a 30.86% increase year-on-year and a 3.60% rise quarter-on-quarter. This is the highest quarterly revenue in the company's recent history, indicating strong market traction.<BR><BR>However, despite this top-line growth, profitability remains a concern. The net profit for Q4 FY26 was ₹1.24 crores, which, while showing a significant 51.22% increase from the previous quarter and a 96.83% rise year-on-year, translates to a modest profit margin of just 5.90%. This is notably lower than the margins achieved in previous periods, reflecting ongoing challenges with cost management and pricing pressures.<BR><BR>Additionally, the company's operating margin, although improved to 10.65% from the previous quarter's 7.54%, is still below historical averages. The elevated tax rate of 38.31% in Q4 FY26 has further eroded profitability, raising concerns about the sustainability of earnings.<BR><BR>Overall, while the revenue growth is a positive sign, the persistent margin compression and high tax burden suggest that the company is facing significant operational challenges. Therefore, the results can be seen as good in terms of sales growth but bad regarding profitability and operational efficiency. Investors should be cautious and monitor how the company addresses these issues moving forward.

Should I buy, sell or hold Source Natural Foods & Herbal Supplements Ltd?

Which are the latest news on Source Natural?

Why is Source Natural Foods & Herbal Supplements Ltd falling/rising?

As of 03-Jun, Source Natural Foods & Herbal Supplements Ltd's stock price is at 107.50, down 5.12% and underperforming the sector. The stock has seen a consistent decline over various time frames, indicating bearish sentiment among investors.

As of 03-Jun, Source Natural Foods & Herbal Supplements Ltd is experiencing a decline in its stock price, currently at 107.50, which reflects a change of -5.8 (-5.12%). The stock has underperformed against the sector by -5.41% today, indicating a significant drop in performance. Although the stock opened with a gain of 3.66% and reached an intraday high of Rs 117.45, it also touched a low of Rs 102, marking a substantial intraday volatility of 7.04%.<BR><BR>Over the past week, the stock has decreased by 4.02%, and its performance over the past month shows a decline of 15.55%. Year-to-date, the stock is down 20.34%, and over the past year, it has fallen by 38.75. This consistent downward trend is further emphasized by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment among investors.<BR><BR>Despite a rise in delivery volume by 23.7% against the 5-day average, the overall performance metrics suggest that the stock is facing significant challenges, leading to its current decline.